Gland Pharma Q4 FY26: margins widen as US momentum and Cenexi recovery lift FY26

Consolidated revenue from operations was INR 17,428 million; adjusted EBITDA was INR 5,244 million (30% margin) and adjusted PAT was INR 3,667 million (21% margin).

FY26 consolidated revenue from operations was INR 64,307 million; adjusted EBITDA was INR 16,826 million (26% margin) and adjusted PAT was INR 10,455 million (16% margin).

The presentation shows FY26 US revenue of INR 34,214 million at group level and INR 33,181 million for base business (Gland).

In Q4 FY26, 8 ANDAs were filed and 11 were approved. Cumulative filings are 388 with 337 approvals and 51 pending.

The company stated it filed 21 RTU bag products and received approvals for 18, with 11 more under development; it cited an addressable US market opportunity of about USD 634 million.

Management guided for 12% to 13% consolidated revenue growth in FY27 on a constant currency basis, excluding any GLP-1 contribution.

The Board recommended a final dividend of INR 20 per equity share for FY26, subject to shareholder approval. The record date stated is August 11, 2026.